{"container_type": "Publication", "source": "AUTHOR_PUBLICATION_ENTRY", "bib": {"title": "Effect of taxane chemotherapy with or without indoximod in metastatic breast cancer: a randomized clinical trial", "pub_year": 2021, "citation": "JAMA oncology 7 (1), 61-69, 2021", "author": "Veronica Mariotti and Hyo Han and Roohi Ismail-Khan and Shou-Ching Tang and Patrick Dillon and Alberto J Montero and Andrew Poklepovic and Susan Melin and Nuhad K Ibrahim and Eugene Kennedy and Nicholas Vahanian and Charles Link and Lucy Tennant and Shelly Schuster and Chris Smith and Oana Danciu and Paul Gilman and Hatem Soliman", "journal": "JAMA oncology", "volume": "7", "number": "1", "pages": "61-69", "publisher": "American Medical Association", "abstract": "Indoleamine 2,3-dioxygenase 1 (IDO1) causes tumor immune suppression. The IDO1 pathway inhibitor indoximod combined with a taxane in patients with ERBB2-negative metastatic breast cancer was tested in a prospective clinical trial.To assess clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane.This phase 2 double-blinded randomized 1:1 placebo-controlled clinical trial enrolled patients at multiple international centers from August 26, 2013, to January 25, 2016. Eligibility criteria included ERBB2-negative metastatic breast cancer, ability to receive taxane therapy, good performance status, normal organ function, no previous immunotherapy use, and no autoimmune disease. The study was discontinued in June 2017 because of lack of efficacy. Data analysis was performed from February 2019 to \u2026"}, "filled": true, "author_pub_id": "zILvqgkAAAAJ:KfVXJnq6lycC", "num_citations": 16, "citedby_url": "/scholar?hl=en&cites=9764346007487230556", "cites_id": ["9764346007487230556"], "pub_url": "https://jamanetwork.com/journals/jamaoncology/article-abstract/2772792", "url_related_articles": "/scholar?oi=bibs&hl=en&q=related:XLJHyPXsgYcJ:scholar.google.com/", "cites_per_year": {"2021": 5, "2022": 8, "2023": 3}}